title: FDG PET and alternative imaging in the management of thyroid carcinoma.
abstract: Differentiated carcinoma of the thyroid are one of rare malignancies that is associated with excellent prognosis. Follow-up with regular thyroglobulin assay and (131)I whole-body scan is capable of detecting residual or recurrent disease with great sensitivity and specificity. However, there is overwhelming evidence to suggest that this approach is not fail-safe due to increasing reports of false negative and false positive results, which may result in missed or unwarranted therapy with (131)I. This article will review the current management of differentiated carcinoma of the thyroid and the possible causes of the reported inadequacy of thyroglobulin and (131)I whole-body scan to detect residual or recurrent disease, and the increasing role of alternative imaging, particularly (18)F-FDG PET in the management of this curable malignancy.
authors.affiliation: Nuclear Medicine, Hammersmith Hospital, Du Cane Road, London, UK. aal-nahhas@hhnt.org
authors.forename: Adil M
authors.initials: AM
authors.lastname: Al-Nahhas
mesh_terms: D019788:Fluorodeoxyglucose F18; D006801:Humans; D007457:Iodine Radioisotopes; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D010346:Patient Care Management / Q000379:methods; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D014055:Tomography, Emission-Computed / Q000379:methods*; D014915:Whole-Body Counting / Q000379:methods
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18